The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases

Figure 1

Proportion of pharmacotherapies recommended by the line of treatment. Data represents the line of therapy a pharmacotherapy was ever recommended for. For example, if a pharmacotherapy was first recommended for first-line and was then later recommended for subsequent lines, it is counted as recommended for both first and subsequent lines. IHD = ischemic heart disease; NSCLC = non-small cell lung cancer; COPD = chronic obstructive pulmonary disease; AD = Alzheimer’s disease; T2D = type 2 diabetes; ADA = American diabetes association; ACE = American college of endocrinology; AACE = American association of clinical endocrinology; US = United States; and EU = European Union.